114 related articles for article (PubMed ID: 26669106)
41. Design, synthesis, and biological evaluation of (E)-3-(4-methanesulfonylphenyl)-2-(aryl)acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases.
Moreau A; Chen QH; Praveen Rao PN; Knaus EE
Bioorg Med Chem; 2006 Dec; 14(23):7716-27. PubMed ID: 16931030
[TBL] [Abstract][Full Text] [Related]
42. Structure-based design of phthalimide derivatives as potential cyclooxygenase-2 (COX-2) inhibitors: anti-inflammatory and analgesic activities.
Alanazi AM; El-Azab AS; Al-Suwaidan IA; ElTahir KE; Asiri YA; Abdel-Aziz NI; Abdel-Aziz AA
Eur J Med Chem; 2015 Mar; 92():115-23. PubMed ID: 25549551
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs).
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2006 Dec; 14(23):7898-909. PubMed ID: 16904331
[TBL] [Abstract][Full Text] [Related]
44. Major isoflavonoid contents of the 1-year-cultivated phytoestrogen-rich herb, Pueraria mirifica.
Cherdshewasart W; Sriwatcharakul S
Biosci Biotechnol Biochem; 2007 Oct; 71(10):2527-33. PubMed ID: 17928711
[TBL] [Abstract][Full Text] [Related]
45. Two new isoflavone glycosides from Pueraria lobata.
Sun YG; Wang SS; Feng JT; Xue XY; Liang XM
J Asian Nat Prod Res; 2008; 10(7-8):729-33. PubMed ID: 18696324
[TBL] [Abstract][Full Text] [Related]
46. Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study.
El-Sayed MA; Abdel-Aziz NI; Abdel-Aziz AA; El-Azab AS; Asiri YA; Eltahir KE
Bioorg Med Chem; 2011 Jun; 19(11):3416-24. PubMed ID: 21570309
[TBL] [Abstract][Full Text] [Related]
47. Steroidal saponins from Smilax china and their anti-inflammatory activities.
Shao B; Guo H; Cui Y; Ye M; Han J; Guo D
Phytochemistry; 2007 Mar; 68(5):623-30. PubMed ID: 17166529
[TBL] [Abstract][Full Text] [Related]
48. Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug.
Hayashi S; Ueno N; Murase A; Nakagawa Y; Takada J
Eur J Med Chem; 2012 Apr; 50():179-95. PubMed ID: 22373734
[TBL] [Abstract][Full Text] [Related]
49. Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides.
Tsai WJ; Shiao YJ; Lin SJ; Chiou WF; Lin LC; Yang TH; Teng CM; Wu TS; Yang LM
Bioorg Med Chem Lett; 2006 Sep; 16(17):4440-3. PubMed ID: 16814546
[TBL] [Abstract][Full Text] [Related]
50. Rotenoids from Boerhaavia diffusa as potential anti-inflammatory agents.
Bairwa K; Singh IN; Roy SK; Grover J; Srivastava A; Jachak SM
J Nat Prod; 2013 Aug; 76(8):1393-8. PubMed ID: 23914900
[TBL] [Abstract][Full Text] [Related]
51. Diarylheterocycle core ring features effect in selective COX-1 inhibition.
Perrone MG; Vitale P; Malerba P; Altomare A; Rizzi R; Lavecchia A; Di Giovanni C; Novellino E; Scilimati A
ChemMedChem; 2012 Apr; 7(4):629-41. PubMed ID: 22278975
[TBL] [Abstract][Full Text] [Related]
52. Phenolic compounds from Pueraria lobata protect PC12 cells against Aβ-induced toxicity.
Choi YH; Hong SS; Shin YS; Hwang BY; Park SY; Lee D
Arch Pharm Res; 2010 Oct; 33(10):1651-4. PubMed ID: 21052940
[TBL] [Abstract][Full Text] [Related]
53. Novel 5-substituted 1H-tetrazoles as cyclooxygenase-2 (COX-2) inhibitors.
Al-Hourani BJ; Sharma SK; Suresh M; Wuest F
Bioorg Med Chem Lett; 2012 Mar; 22(6):2235-8. PubMed ID: 22341941
[TBL] [Abstract][Full Text] [Related]
54. Synthesis of new ibuprofen derivatives with their in silico and in vitro cyclooxygenase-2 inhibitions.
Gundogdu-Hizliates C; Alyuruk H; Gocmenturk M; Ergun Y; Cavas L
Bioorg Chem; 2014 Feb; 52():8-15. PubMed ID: 24270352
[TBL] [Abstract][Full Text] [Related]
55. Isolation of two new C-glucofuranosyl isoflavones from Pueraria lobata (Wild.) Ohwi with HPLC-MS guiding analysis.
Zhang HJ; Yang XP; Wang KW
J Asian Nat Prod Res; 2010 Apr; 12(4):293-9. PubMed ID: 20419540
[TBL] [Abstract][Full Text] [Related]
56. Aspirin analogues as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, nitric oxide release, molecular modeling, and biological evaluation as anti-inflammatory agents.
Kaur J; Bhardwaj A; Huang Z; Knaus EE
ChemMedChem; 2012 Jan; 7(1):144-50. PubMed ID: 22095955
[TBL] [Abstract][Full Text] [Related]
57. Structural and Electronic Factors Influencing the Selective Inhibition of COX-2.
Aksakal F; Shvets N; Khairullina V; Dimoglo A
Mini Rev Med Chem; 2016; 16(7):579-94. PubMed ID: 26471968
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of glycolamide esters of indomethacin as potential cyclooxygenase-2 (COX-2) inhibitors.
Khanna S; Madan M; Vangoori A; Banerjee R; Thaimattam R; Jafar Sadik Basha SK; Ramesh M; Casturi SR; Pal M
Bioorg Med Chem; 2006 Jul; 14(14):4820-33. PubMed ID: 16581252
[TBL] [Abstract][Full Text] [Related]
59. Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors.
Zarghi A; Kakhgi S; Hadipoor A; Daraee B; Dadrass OG; Hedayati M
Bioorg Med Chem Lett; 2008 Feb; 18(4):1336-9. PubMed ID: 18226898
[TBL] [Abstract][Full Text] [Related]
60. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
Hayashi S; Sumi Y; Ueno N; Murase A; Takada J
Biochem Pharmacol; 2011 Oct; 82(7):755-68. PubMed ID: 21741371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
